Theo Marsh

Lutein and zeaxanthin may support selective retinal pathways, but evidence is limited; outcomes depend on dose, formulation, and matching use to trial context.

Ginkgo is widely sold for memory, but evidence is weak or mixed. If using it, check medication interactions first and do not replace clinical care.

Magnesium may help some people with insomnia, but trial evidence is thin. Dose, kidney function and the distinction between food and pills matter.

Beta-alanine may help repeated hard efforts, but benefits are narrow; tingling is not a quality signal, and long-term safety remains uncertain.

Lion’s mane has small human studies behind its brain claims, but dose, extract type, and product testing matter more than the marketing suggests.

Red yeast rice can lower LDL when it contains monacolin K, but variable dosing, statin-like risks, and contamination make the product harder to judge.

Rhodiola may help some fatigue symptoms, but evidence remains modest and product quality varies. Here is what dose, safety, and sourcing really mean.

Creatine keeps coming back as the supplement with the strongest claim-to-usage gap in longevity media. It is sold as a brain tonic, a metabolic reset, and sometimes a prevention strategy for every age-related decline. That framing overstates the evidence. The strongest claim the field can defend is this: in short, high-intensity training contexts, creatine monohydrate … Read more

Taurine has intriguing animal and metabolic data, but human evidence is still too thin to treat it as an anti-ageing supplement for healthy adults.

NMN raises blood NAD+ in trials, but longevity claims outrun the evidence. What doses studies use, what they show, and why product labels matter.